3TR-ABC - TEZEBIO
Northern Ireland Clinical Research Facility
Principal Investigator/s: Dr Jane McDowell
Name of the Study: TEZEBIO – 3TR ABC
Why is this Study important?
The success of biologics in asthma has led to the renewed interest in what is asthma remission and how can it be achieved? (Reference 7). Tezepelumab is especially interesting in the context of remission, due to its effect on the very initiation of inflammation in the epithelium combined with the clinical effects across different phenotypes (Reference 5,8). The mechanisms underlying asthma remission and the potential biomarkers beyond blood eosinophils and FeNO of associated with asthma remission following treatment with Tezepelumab is unknown.
What is the Research question/aim?:
Biological therapies targeting T2-mediated immunity have consistently reduced exacerbations and the requirement for regular prednisolone therapy (Reference 1-4). Tezepelumab is a novel, highly effective and well-tolerated medication that helps people with severe asthma of all types avoid asthma attacks (Reference 5): Importantly, Tezepelumab decreases asthma flare-ups across different types of severe asthma, as opposed to already approved biologics that have a narrower spectrum of action (Reference 6).
What the Study involves:
A 36 month multi-centre observational study of patients with severe asthma following initiation of treatment with Tezepelumab (anti-TSLP) as part of their standard of care.
Subjects will be extensively characterized at baseline; reviewed throughout the year with formal clinical and biological assessment at 4, 16, 52 weeks, 2 years and 3 years. Asthma remission will be defined for each domain: asthma control, lung function, and exacerbations as a composite measure and independently. Biomarkers and multi-omic analysis will be undertaken in the biosamples to determine biological pathways and bio-signatures associated with asthma remission.
Who can take part in the Study?
Patients with severe asthma
Contact Information:
02895043902
Respiratory Research Office
Belfast City Hospital
51 Lisburn Road
Belfast, BT9 7AB
Location:
NI Clinical Research Facility,
U Floor, Belfast City Hospital,
Lisburn Road, Belfast, BT9 7AB
Tel:+44 (0)28 9504 0342
Email:NICRF@qub.ac.uk
